An Ozempic rival is getting closer to market — and it's hurting Novo Nordisk and Eli Lilly stock
26.07.2024 00:16:05 Yorum Yok Görüntülenme
Shares of Novo Nordisk and Eli Lilly slid Thursday after San Diego-based Viking Therapeutics announced that it’s advancing an experimental weight loss drug to a late-stage clinical trial.